The constitutive activation in ovarian cancer is a result of amplification of pathway components like PI3K subunits (p110), AKT isoforms (AKT1, AKT2, or AKT3), or members of the mTOR complexes (RICTOR, RAPTOR). The gene discussed is AKT3; the disease is ovarian carcinoma.